TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23221981

Group type: EXPERIMENTAL
Intervention: ALVAC-HIV vCP1521 vaccine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 60
Study: 21227012

Group type: EXPERIMENTAL
Intervention: Controlled ovarian hyperstimulation (COH) using triptorelin 0.1 mg/day SC and recombinant FSH 150 - 300 IU/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Modified natural cycle (MNC) treatment using HMG 150 IU/day IM if serum oestradiol was ≤ 50 pg/ml
Number of subjects: 60
Study: 17159974

Group type: EXPERIMENTAL
Intervention: Conjunctival limbal autograft (CLAU) and amniotic membrane transplantation (AMT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intraoperative mitomycin C (MMC) (0.02%, 3 min) and amniotic membrane transplantation (AMT)
Number of subjects: 40
Study: 16868345

Group type: EXPERIMENTAL
Intervention: Patients with autonomic failure
Number of subjects: 28

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 28
Study: 14521274

Group type: EXPERIMENTAL
Intervention: P300 latency in patients with impaired/borderline memory
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: P300 latency in patients with normal WMS-III/MMSE and subjective memory complaints
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: P300 latency increase per year
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: P300 voltage decrease per year
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: P300 latency and memory impairment in females vs males
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: WMS-III memory decline in females
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: WMS-III memory decline in males
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: MMSE memory decline
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: P300 latency as a predictor of WMS-III impairment
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: P300 latency identifying borderline/impaired memory
Number of subjects: 1506
Study: 10382235

Group type: EXPERIMENTAL
Intervention: BIPAP therapy (n = 47)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Unassisted oxygen therapy (n = 46)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Elective extubation
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Unplanned extubation
Number of subjects: 93
Study: 9179160

Group type: EXPERIMENTAL
Intervention: Calcitonin gene-related peptide (CGRP) and substance P (SP) staining in the neuroma
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Mast cell accumulation in the neuroma
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Tyrosine hydroxylase staining
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Comparison to animal neuroma model
Number of subjects: 1
Study: 8113643

Group type: EXPERIMENTAL
Intervention: Cloxacillin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 0
Study: 2871492

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (1.5 million IU, one-hour infusion)
Number of subjects: 1741

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1741
Study: 31549624

Group type: EXPERIMENTAL
Intervention: FDC tablet containing amlodipine and rosuvastatin
Number of subjects: 36

Group type: COMPARATOR
Intervention: Individual tablets of amlodipine and rosuvastatin (reference drugs)
Number of subjects: 36
Study: 30032806

Group type: EXPERIMENTAL
Intervention: Perampanel (PER) adjunctive therapy
Number of subjects: 66
Study: 27876084

Group type: EXPERIMENTAL
Intervention: Fluid Sparing resuscitation strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care (control)
Number of subjects: 0
Study: 24641638

Group type: EXPERIMENTAL
Intervention: Prophylactic epidural blood patch
Number of subjects: 109

Group type: COMPARATOR
Intervention: Therapeutic epidural blood patch
Number of subjects: 109
Study: 22054531

Group type: EXPERIMENTAL
Intervention: Community prevention model (CPM) consisting of community mobilization strategy and environmental strategies targeting homes, schools, and retail outlets, duration of 21 months.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned in the abstract, details not available.
Number of subjects: 0
Study: 21128849

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 22
Study: 18689362

Group type: EXPERIMENTAL
Intervention: 5:4:1 emulsion (50% MCT, 40% LCT, 10% FO)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 5:5 emulsion (50% MCT, 50% LCT)
Number of subjects: 8
Study: 16117979

Group type: EXPERIMENTAL
Intervention: Amlodipine adipate
Number of subjects: 211

Group type: COMPARATOR
Intervention: Amlodipine besylate
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 211
Study: 12687444

Group type: EXPERIMENTAL
Intervention: ACDF with a cervical carbon‐fibre intervertebral fusion cage
Number of subjects: 103

Group type: COMPARATOR
Intervention: Cloward procedure
Number of subjects: 103
Study: 10588404

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lithium plus Carbamazepine
Number of subjects: 30
Study: 8567109

Group type: EXPERIMENTAL
Intervention: Screening tests including PSA serum determination, rectal examination, and transrectal ultrasonography.
Number of subjects: 7200

Group type: EXPERIMENTAL
Intervention: Biopsy following positive screening results.
Number of subjects: 7200
Study: 1427129

Group type: EXPERIMENTAL
Intervention: Aerobic exercise class
Number of subjects: 87

Group type: COMPARATOR
Intervention: Health education group
Number of subjects: 87
Study: 6728881

Group type: EXPERIMENTAL
Intervention: Alcohol (0.66 abs alc/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31254850

Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-Invasive Ventilation (NIV)
Number of subjects: 20
Study: 29878867

Group type: EXPERIMENTAL
Intervention: CT-cetux-RT (cetuximab plus radiotherapy with concurrent carboplatin and fluorouracil)
Number of subjects: 406

Group type: COMPARATOR
Intervention: cetux-RT (cetuximab plus radiotherapy)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: CT-cetux-RT
Number of subjects: 406

Group type: COMPARATOR
Intervention: cetux-RT
Number of subjects: 406
Study: 27246138

Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention (PAI)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard presurgical care control (SC)
Number of subjects: 75
Study: 24840638

Group type: EXPERIMENTAL
Intervention: Percentile incentive schedule
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Fixed criterion incentive schedule
Number of subjects: 93

Group type: COMPARATOR
Intervention: Random incentive schedule
Number of subjects: 93
Study: 23094708

Group type: EXPERIMENTAL
Intervention: MN-221 (bedoradrine sulfate) via intravenous infusion
Number of subjects: 40
Study: 20823434

Group type: EXPERIMENTAL
Intervention: Switch to nevirapine-based therapy (n = 96)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Control group continued to receive ritonavir‐boosted lopinavir, stavudine, and lamivudine (n = 99)
Number of subjects: 195
Study: 17680841

Group type: EXPERIMENTAL
Intervention: travoprost 0.004%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: latanoprost 0.005%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: bimatoprost 0.03%
Number of subjects: 60
Study: 16273650

Group type: EXPERIMENTAL
Intervention: TPN supplemented with 0.417 g L-alanyl-L-glutamine (Ala-Gln)/kg per day
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional TPN solution receiving 1.5 g amino acids/kg per day
Number of subjects: 48
Study: 11812714

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's at 20 mL/kg starting at the time of spinal block
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's at 20 mL/kg starting 20 min before spinal block
Number of subjects: 404

Group type: COMPARATOR
Intervention: Placebo (lactated Ringer's solution at 1-2 mL/min)
Number of subjects: 404
Study: 10362384

Group type: EXPERIMENTAL
Intervention: Vibratory stimulation (44 Hz, acceleration of about 30 m x s(‐2)) during bilateral biceps curl exercises
Number of subjects: 28

Group type: COMPARATOR
Intervention: No vibratory stimulation (control) during bilateral biceps curl exercises
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Vibratory stimulation
Number of subjects: 28
Study: 7741778

Group type: EXPERIMENTAL
Intervention: 100 mg tablet formulation of tiracizine
Number of subjects: 12
Study: 2203300

Group type: EXPERIMENTAL
Intervention: FCE 22891 (oral prodrug of FCE 22101)
Number of subjects: 0
Study: 7048188

Group type: EXPERIMENTAL
Intervention: Benzocaine (7.5% in propylene glycol gel)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 31746553

Group type: EXPERIMENTAL
Intervention: IBT-liraglutide
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Multicomponent
Number of subjects: 150

Group type: COMPARATOR
Intervention: IBT-alone
Number of subjects: 150
Study: 29547480

Group type: EXPERIMENTAL
Intervention: Gaze stability exercises
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sham group (saccadic eye movement exercises)
Number of subjects: 41
Study: 29797932

Group type: EXPERIMENTAL
Intervention: 0.5% Lugol liquid iodine staining
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 1.0% Lugol liquid iodine staining
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 1.5% Lugol liquid iodine staining
Number of subjects: 90

Group type: COMPARATOR
Intervention: NBI examination
Number of subjects: 90
Study: 24119221

Group type: EXPERIMENTAL
Intervention: Laser peripheral iridotomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative measurements
Number of subjects: 0
Study: 21922264

Group type: EXPERIMENTAL
Intervention: Diet, exercise and lower body pressure intervention (DEP)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Diet plus exercise (DE)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 86
Study: 20832244

Group type: EXPERIMENTAL
Intervention: Contrast Enhanced Ultrasound (CEU)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard Clinical Monitoring (SCM)
Number of subjects: 36
Study: 16904812

Group type: EXPERIMENTAL
Intervention: D2-dopamine antagonist sulpiride during n-back working memory tasks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 16368447

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (N-acetylcysteine 600 mg/d, vitamin E 300 mg/d, vitamin C 250 mg/d)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Standardized moderate-fat meal (without antioxidant supplementation)
Number of subjects: 138
Study: 11903031

Group type: EXPERIMENTAL
Intervention: Perioperative β‐blockade
Number of subjects: 6
Study: 9463746

Group type: EXPERIMENTAL
Intervention: CA19-9
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CEA
Number of subjects: 150
Study: 8590792

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 162

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 162
Study: 2692652

Group type: EXPERIMENTAL
Intervention: Epirubicin 20 mg weekly bolus injection
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Epirubicin 40 mg weekly bolus injection
Number of subjects: 62

Group type: COMPARATOR
Intervention: Epirubicin 24-h infusion
Number of subjects: 62
Study: 341376

Group type: EXPERIMENTAL
Intervention: Neomycin
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Neomycin-phthalylsulfathiazole
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Neomycin-erythromycin base
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 91
Study: 31866533

Group type: EXPERIMENTAL
Intervention: Methylaminolevulinate (MAL)‐based PDT in three sessions with a light dose of 90 J/cm2 delivered in a single fraction in each session (Group I)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Methylaminolevulinate (MAL)‐based PDT in three sessions with the light dose delivered in three fractions (Group II)
Number of subjects: 60
Study: 31527041

Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 188

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 188
Study: 27755649

Group type: EXPERIMENTAL
Intervention: Online evaluative conditioning (EC)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 184
Study: 26181538

Group type: EXPERIMENTAL
Intervention: Forefoot abduct shoes (FAS) with orthopedic shoes (OS)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: DB splint + orthopedic shoes (OS)
Number of subjects: 53

Group type: COMPARATOR
Intervention: DB splint
Number of subjects: 53
Study: 23577088

Group type: EXPERIMENTAL
Intervention: Tailored information packs provided to intervention group politicians
Number of subjects: 617

Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract)
Number of subjects: 617
Study: 20700054

Group type: EXPERIMENTAL
Intervention: Multidisciplinary lifestyle modification programme
Number of subjects: 325

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 325
Study: 19081156

Group type: EXPERIMENTAL
Intervention: 0.01% rh-PDGF-BB gel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard wound care
Number of subjects: 20
Study: 16750670

Group type: EXPERIMENTAL
Intervention: Successful reperfusion by primary PCI (TIMI 3 flow)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Unsuccessful PCI (TIMI < 3 flow)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Improved myocardial blush grade
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Multivariate analysis of myocardial perfusion (TIMI 3 flow and myocardial blush grade 3)
Number of subjects: 364
Study: 15228971

Group type: EXPERIMENTAL
Intervention: Telephone counseling intervention
Number of subjects: 221

Group type: COMPARATOR
Intervention: Quit-manual comparison group
Number of subjects: 221
Study: 11694669

Group type: EXPERIMENTAL
Intervention: Psychological distress at baseline
Number of subjects: 522
Study: 9203721

Group type: EXPERIMENTAL
Intervention: IPV followed by OPV (sequential schedules)
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: IPV only
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: OPV only
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Two IPV doses followed by two OPV doses (optimal schedule)
Number of subjects: 510

Group type: COMPARATOR
Intervention: Prior OPV doses (two or more)
Number of subjects: 510
Study: 7968593

Group type: EXPERIMENTAL
Intervention: Monophasic combination of 30 micrograms ethinyl estradiol and 75 micrograms gestodene for 12 consecutive cycles
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (no hormonal treatment)
Number of subjects: 13
Study: 3377156

Group type: EXPERIMENTAL
Intervention: oral metoclopramide
Number of subjects: 101

Group type: COMPARATOR
Intervention: standardised anaesthesia
Number of subjects: 101
Study: 30033117

Group type: EXPERIMENTAL
Intervention: Selective Internal Radiation Therapy (SIRT) plus mFOLFOX6 chemotherapy
Number of subjects: 739

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 739
Study: 27536069

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg daily for 6 months
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (PCOS without treatment)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (lean healthy controls)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 27
Study: 25711607

Group type: EXPERIMENTAL
Intervention: Delayed-dose oral rotavirus vaccine
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Injectable polio vaccine replacing one dose of oral polio vaccine
Number of subjects: 700
Study: 23865123

Group type: EXPERIMENTAL
Intervention: Ginger in capsule form for 3 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 20798226

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery (n=80)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Intensive lifestyle intervention (n=66)
Number of subjects: 146
Study: 18258768

Group type: EXPERIMENTAL
Intervention: Group-based high-intensity interval training program (aerobic, resistance, flexibility, and balance activities), twice per week for 16 weeks.
Number of subjects: 4
Study: 15973647

Group type: EXPERIMENTAL
Intervention: Spanish-speaking participants
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: English-speaking participants
Number of subjects: 55

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 55
Study: 15062917

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 100
Study: 11251134

Group type: EXPERIMENTAL
Intervention: Dipyrone
Number of subjects: 151

Group type: COMPARATOR
Intervention: Tramadol
Number of subjects: 151
Study: 9228372

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 70 mg/kg, n=14
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: L-2-oxothiazolidine-4-carboxylate (Procysteine; OTZ) 63 mg/kg, n=17
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo, n=15
Number of subjects: 46
Study: 8498367

Group type: EXPERIMENTAL
Intervention: Intervention diet A (group A)
Number of subjects: 621

Group type: COMPARATOR
Intervention: Control diet B (group B)
Number of subjects: 621
Study: 3431824

Group type: EXPERIMENTAL
Intervention: Tono-Pen #1
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Tono-Pen #2
Number of subjects: 103

Group type: COMPARATOR
Intervention: Goldmann applanation tonometer
Number of subjects: 103
Study: 31206400

Group type: EXPERIMENTAL
Intervention: High-fiber DASH diet (32 g/d)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: High sodium intake (150 mmol/d)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Low-fiber Western diet (control)
Number of subjects: 412
Study: 30055723

Group type: EXPERIMENTAL
Intervention: Narrative-based language intervention (NBLI) group therapy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Narrative-based language intervention (NBLI) private sessions
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional speech therapy (CST)
Number of subjects: 36
Study: 27022997

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (MI) group - healthy nutrition educational program in addition to a healthy daily meal
Number of subjects: 3627

Group type: COMPARATOR
Intervention: Environmental intervention group - received a healthy daily meal
Number of subjects: 3627
Study: 25034548

Group type: EXPERIMENTAL
Intervention: Concurrent physical training program (CPTP) consisting of running training in the Fatmax intensity zone and strength training (squats and bench presses); three 40‐minute sessions a week for 24 weeks
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 71
Study: 22499016

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 20032570

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg per day
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 18635482

Group type: EXPERIMENTAL
Intervention: Passive safety catheter
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Active safety catheter
Number of subjects: 759

Group type: COMPARATOR
Intervention: Nonsafety classic catheter
Number of subjects: 759
Study: 16289514

Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg intravenous (i.v.) or oral
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Vancomycin 1g i.v. every 12 h
Number of subjects: 1200
Study: 12045059

Group type: EXPERIMENTAL
Intervention: Laser in situ keratomileusis
Number of subjects: 100
Study: 9464757

Group type: EXPERIMENTAL
Intervention: Increased preload (PL)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Normal preload with inotropes (INO)
Number of subjects: 39
Study: 7839377

Group type: EXPERIMENTAL
Intervention: Exercise training group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 1699308

Group type: EXPERIMENTAL
Intervention: Adjusted hypervolemic hemodilution
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 47
Study: 340137

Group type: EXPERIMENTAL
Intervention: salsalate (3 g/day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: indomethacin (75 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study: 30301829

Group type: EXPERIMENTAL
Intervention: AR‐V7+ patients receiving taxane therapy (docetaxel or cabazitaxel)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: ARv567es+ patients receiving taxane therapy
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: AR‐V7+ patients
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: AR‐V7- patients
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: ARv567es+ patients
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: ARv567es- patients
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: AR‐V7-, ARv567es- patients
Number of subjects: 54
Study: 28367891

Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal treatment (NSPT)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Oral hygiene instruction (OHI)
Number of subjects: 56
Study: 26252987

Group type: EXPERIMENTAL
Intervention: Retractorless technique (group I)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Fixed retractors (group II)
Number of subjects: 47
Study: 23948537

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 478

Group type: COMPARATOR
Intervention: Community Service (CS)
Number of subjects: 478
Study: 21775562

Group type: EXPERIMENTAL
Intervention: Fish-oil-based lipid emulsion (FOLE) at a dose of 1 g · kg(‐1) · d(‐1) for ≥1 month
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Fish-oil-based lipid emulsion (FOLE)
Number of subjects: 79
Study: 19812357

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (3% NaCl)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Isotonic saline (0.9% NaCl)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (3% NaCl) at BT-treated sites
Number of subjects: 7

Group type: COMPARATOR
Intervention: Isotonic saline (0.9% NaCl) at BT-treated sites
Number of subjects: 7
Study: 17383291

Group type: EXPERIMENTAL
Intervention: Carvedilol (up-titrated to 25 mg BID)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Enalapril (up-titrated to 20 mg BID) and spironolactone (25 mg QD)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42